Beren Therapeutics Receives FDA Breakthrough Therapy Designation for Adrabetadex
Written by Emily J. Thompson, Senior Investment Analyst
Source: Businesswire
Updated: 1 hour ago0mins
- FDA Designation: Beren Therapeutics' subsidiary Mandos has received Breakthrough Therapy Designation from the FDA for adrabetadex, aimed at expediting drug development for infantile-onset Niemann-Pick disease type C, marking a significant advancement for the company in the rare disease sector.
- Survival Rate Improvement: The FDA's decision was based on an external survival analysis indicating that adrabetadex significantly improves survival rates in infantile-onset NPC patients, suggesting the drug's potential value and market prospects in clinical applications.
- Historical Context: Adrabetadex previously received BTD in 2016, but the designation was rescinded in 2018 due to clinical trial data; Beren's acquisition of the program in 2021 and subsequent collaboration with the FDA to regain this designation demonstrates the company's strong commitment to the drug.
- Future Plans: Beren plans to submit a New Drug Application (NDA) soon and expects adrabetadex to qualify for Priority Review, further enhancing its competitiveness and impact in the market.
BRT.N
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on BRT
Wall Street analysts forecast BRT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRT is 18.50 USD with a low forecast of 16.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 14.500
Low
16.00
Averages
18.50
High
20.00
Current: 14.500
Low
16.00
Averages
18.50
High
20.00
Citizens JMP
Outperform
downgrade
$24 -> $20
2025-11-18
Reason
Citizens JMP
Price Target
$24 -> $20
2025-11-18
downgrade
Outperform
Reason
Citizens JMP lowered the firm's price target on BRT Apartments to $20 from $24 and keeps an Outperform rating on the shares following the Q3 print. The firm expects fundamentals to provide a favorable backdrop next year, and thinks additional capital could be accessed through debt refinancing in the future to unlock opportunities for value creation, the analyst tells investors in a research note.
B. Riley
Buy
maintain
$21
2025-10-01
Reason
B. Riley
Price Target
$21
2025-10-01
maintain
Buy
Reason
B. Riley raised the firm's price target on BRT Apartments to $21 from $19.50 and keeps a Buy rating on the shares. The firm sees the company benefitting from the lower interest rate environment. BRT offers "compelling value" at current share levels despite its small cap size and limited trading volume, the analyst tells investors in a research note.
B. Riley Securities
John Massocca
Strong Buy
Maintains
$22 → $21
2025-03-27
Reason
B. Riley Securities
John Massocca
Price Target
$22 → $21
2025-03-27
Maintains
Strong Buy
Reason
B. Riley lowered the firm's price target on BRT Apartments to $21 from $22 and keeps a Buy rating on the shares. The company's Q4 results reflected the vulnerability of the Sunbelt apartment market, given continued new supply pressures and upward pressure on operating expenses, the analyst tells investors in a research note. However, the firm believes these headwinds are not enough to justify BRT's current valuation discount.
See All Ratings
About BRT
BRT Apartments Corp. is a real estate investment trust that owns, operates, and to a lesser extent, holds interest in joint ventures that own and operate multifamily properties. The Company owns or has interests in over 31 multifamily properties with 8,311units in 11 states and has preferred equity investments in two multi-family properties. Generally, its multifamily properties are garden apartments and, to a lesser extent, mid-rise or town home style properties that provide residents with amenities, such as a clubhouse, swimming pool, laundry facilities and Internet access. In addition to its multifamily properties and preferred loan investments, the Company owns assets, and in particular, real estate assets. Its properties include Silvana Oaks Apartments, Avondale Station, Brixworth at Bridge Street, Newbridge Commons, Crossings of Bellevue, Avalon Apartments, Parkway Grande, Woodland Trails, Grove at River Place, Kilburn Crossing, The Woodland Apartments, and others.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?